Impact of Age on Treatment Patterns and Outcomes in Patients With Non‐Metastatic Castration‐Resistant Prostate Cancer

Authors:

Abstract
Objectives: To evaluate the impact of age on treatment patterns and outcomes in patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). Methods: We conducted a retrospective multicenter analysis of 428 patients with nmCRPC from 25 tertiary centers (2002–2022). Patients were divided into two age groups: < 80 and ≥ 80 years. The outcomes included cancer‐specific survival (CSS), overall survival (OS), and progression‐free survival (PFS). Results: Among 428 patients (median follow‐up, 32.5 months), performance status (PS) 0 was more frequent in < 80 vs. ≥ 80 years (78% vs. 58%, p < 0.001). Use of first‐line androgen receptor signaling inhibitors (ARSIs) was similar (58% vs. 59%, p = 0.83) among all, whereas any‐line docetaxel use was less common in patients aged ≥ 80 years (33% vs. 9% for < 80 vs. ≥ 80, p < 0.001). Five‐year CSS was 76.5% vs. 63.7% ( p = 0.002) and five‐year OS 73.8% vs. 59.9% ( p = 0.006) for < 80 vs. ≥ 80 years, respectively. Time‐to‐treatment failure was shorter in patients aged ≥ 80 years ( p = 0.04). Conclusion: Maintaining PS and managing ARSI‐related adverse events are essential in older patients with nmCRPC and may preserve their eligibility for chemotherapy and improve their prognosis.

This publication has 20 references indexed in Scilit: